Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Davar, Diwakar; Morrison, Robert M.; Dzutsev, Amiran K.; Karunamurthy, Arivarasan; Chauvin, Joe-Marc; Amatore, Florent; Deutsch, Julie S.; Das Neves, Rodrigo X.; Rodrigues, Richard R.; McCulloch, John A.; Wang, Hong; Hartman, Douglas J.; Badger, Jonathan H.; Fernandes, Miriam R.; Bai, Yulong; Sun, Jie; Cole, Alicia M.; Aggarwal, Poonam; Fang, Jennifer R.; Deitrick, Christopher; Bao, Riyue; Duvvuri, Umamaheswar; Sridharan, Shaum S.; Kim, Seungwon W.; A. Choudry, Haroon; Holtzman, Matthew P.; Pingpank, James F.; O'Toole, James Patrick; DeBlasio, Richelle; Jin, Yang; Ding, Quanquan; Gao, Wentao; Groetsch, Christopher; Pagliano, Ornella; Rose, Amy; Urban, Corey; Singh, Jagjit; Divarkar, Prajan; Mauro, David; Bobilev, Dmitri; Wooldridge, James; Krieg, Arthur M.; Fury, Matthew G.; Whiteaker, Jeffrey R.; Zhao, Lei; Paulovich, Amanda G.; Najjar, Yana G.; Luke, Jason J.; Kirkwood, John M.; Taube, Janis M.; Park, Hyun Jung; Trinchieri, Giorgio; Zarour, Hassane M.

doi:10.1016/j.ccell.2024.10.007

Cancer Cell

2024

DOI: 10.1016/j.ccell.2024.10.007

|View full text |Cite

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Diwakar Davar,

Robert M. Morrison,

Amiran K. Dzutsev

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma

Smithy,

Postow

2024

Cancer Cell

View full text Add to dashboard Cite

Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma

Smithy,

Postow

2024

Cancer Cell

View full text Add to dashboard Cite

Neoadjuvant Therapy

Hyngstrom

2024

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cited by 2 publications

References 102 publications

Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma

Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma

Neoadjuvant Therapy

Contact Info

Product

Resources

About